IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE,…
News
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE,…
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines…
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines…
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical…
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical…
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects…
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects…
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
$8 million commitments received in a strongly supported placement to new and existing institutional investors …
Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
$8 million commitments received in a strongly supported placement to new and existing institutional investors …
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA® PRINCETON, N.J., Sept….
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA® PRINCETON, N.J., Sept….
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2023 (GLOBE NEWSWIRE) — Science 37 announced today that…
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2023 (GLOBE NEWSWIRE) — Science 37 announced today that…
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease…
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease…
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage…
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage…